Oramed Pharmaceuticals Inc has joined forces with Biotechnology company Premas Biotech to develop an oral vaccine for COVID-19, according to a Friday press release from Business Wire. According to the Co-Founder and Director of Premas Biotech Prabuddha Kundu, this oral vaccine brings together Oramed’s oral protein delivery platform “POD” and Premas’s “D-Crypt” platform. He says that Oramed’s experience in several oral trials has given them an advantage in efforts to discover an oral vaccine. Oramed CEO Nadav Kidron meanwhile expressed hope that this oral vaccine could help in ending the global pandemic. Oravas was established earlier this year by Oramed Pharmaceuticals Inc, and utilizes technologies from Premas Biotech in its oral vaccine research.

Source: Egypt Independent March 23, 2021 15:11 UTC